Granahan Investment Management LLC cut its position in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 15.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 667,057 shares of the company's stock after selling 119,312 shares during the period. Granahan Investment Management LLC owned approximately 2.75% of OrthoPediatrics worth $16,430,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the company. Millennium Management LLC purchased a new stake in shares of OrthoPediatrics in the fourth quarter worth about $9,798,000. Point72 Asset Management L.P. purchased a new position in OrthoPediatrics during the fourth quarter worth approximately $7,450,000. Wellington Management Group LLP boosted its position in OrthoPediatrics by 20.2% during the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock worth $24,601,000 after purchasing an additional 178,078 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its position in OrthoPediatrics by 1,607.0% during the first quarter. Paradigm Capital Management Inc. NY now owns 170,700 shares of the company's stock worth $4,204,000 after purchasing an additional 160,700 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in OrthoPediatrics by 29.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock worth $15,576,000 after purchasing an additional 152,681 shares in the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at OrthoPediatrics
In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of the firm's stock in a transaction on Thursday, August 21st. The stock was bought at an average cost of $19.41 per share, with a total value of $98,525.16. Following the acquisition, the chief financial officer directly owned 213,065 shares of the company's stock, valued at approximately $4,135,591.65. This represents a 2.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 31.80% of the stock is owned by company insiders.
OrthoPediatrics Stock Down 3.5%
KIDS traded down $0.72 on Wednesday, hitting $19.77. 52,529 shares of the company were exchanged, compared to its average volume of 192,753. OrthoPediatrics Corp. has a twelve month low of $16.59 and a twelve month high of $33.14. The company has a market cap of $495.63 million, a price-to-earnings ratio of -11.04 and a beta of 1.06. The company has a current ratio of 6.66, a quick ratio of 3.43 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $21.05 and a two-hundred day moving average price of $21.94.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. The company had revenue of $61.08 million during the quarter, compared to the consensus estimate of $61.40 million. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%. OrthoPediatrics has set its FY 2025 guidance at EPS. On average, equities analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Citigroup reiterated a "market outperform" rating on shares of OrthoPediatrics in a research report on Friday, August 8th. Wall Street Zen raised OrthoPediatrics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. JMP Securities set a $35.00 price target on OrthoPediatrics and gave the company a "market outperform" rating in a report on Friday, August 8th. Finally, BTIG Research cut their price target on OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, OrthoPediatrics presently has an average rating of "Moderate Buy" and an average target price of $34.14.
Get Our Latest Report on OrthoPediatrics
OrthoPediatrics Company Profile
(
Free Report)
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Further Reading
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
